PATH VACCINE SOLUTIONS
2201 WESTLAKE AVENUE NO 200, SEATTLE, WA 98121 www.path.org

---

Organizations Filed Purposes: THE MISSION OF PATH VACCINE SOLUTIONS (PVS) IS TO IMPROVE THE HEALTH OF CHILDREN IN LOW-RESOURCE SETTINGS BY ACCELERATING THE DEVELOPMENT OF VACCINES THAT WILL BE EFFECTIVE AND AFFORDABLE FOR THOSE WHO NEED THEM MOST. (CONTINUED ON SCHEDULE O)FROM INITIAL DISCOVERY THROUGH CLINICAL TRIALS, PVS WORKS WITH COMMERCIAL PARTNERS, SUCH AS VACCINE MANUFACTURERS AND BIOTECHNOLOGY FIRMS, AND NONPROFIT PARTNERS, SUCH AS UNIVERSITIES AND RESEARCH INSTITUTIONS, TO SHORTEN THE TIMELINE FOR VACCINE DEVELOPMENT. FOR THESE PARTNERS, PVS PROVIDES FUNDING AND EXPERTISE IN PRECLINICAL DEVELOPMENT, MANUFACTURING, REGULATORY, AND CLINICAL DEVELOPMENT, WITH A FOCUS ON LOW-RESOURCE SETTINGS. IN RETURN, PARTNERS AGREE TO TERMS THAT HELP ENSURE THE RESULTING PRODUCTS ARE AFFORDABLE AND AVAILABLE IN PUBLIC IMMUNIZATION PROGRAMS IN LOW- AND MIDDLE-INCOME COUNTRIES.

SEE PART III, LINE 1.

IN 2019, PVS CONTINUED OUR FIGHT AGAINST DIARRHEAL DISEASES, THE SECOND-LEADING CAUSE OF DEATH AMONG CHILDREN IN LOW-INCOME COUNTRIES. TO COMBAT ROTAVIRUS, A MAJOR CAUSE OF SEVERE DIARRHEA, WE CONTINUED CLINICAL DEVELOPMENT OF A NONREPLICATING ROTAVIRUS VACCINE CANDIDATE BY BEGINNING A PHASE 3 EFFICACY STUDY IN ZAMBIA, THE FIRST OF FOUR COUNTRIES PARTICIPATING IN THIS STUDY. THIS VACCINE CANDIDATE IS ADMINISTERED AS AN INTRAMUSCULAR INJECTION AND COULD POTENTIALLY OVERCOME THE LOWER EFFICACY LEVELS SEEN IN LOW-RESOURCE SETTINGS FOR ORAL, LIVE ATTENUATED ROTAVIRUS VACCINES. (CONTINUED ON SCHEDULE O).IN ADDITION, PVS HOSTED A MEETING IN GENEVA IN JUNE 2019 THAT BROUGHT TOGETHER VACCINE DEVELOPERS AND MANUFACTURERS ENGAGED IN NEXT-GENERATION ROTAVIRUS VACCINE RESEARCH AND DEVELOPMENT TO BETTER DEFINE THE PROGRESS OF THESE NOVEL VACCINE CANDIDATES. FINALLY, PVS INITIATED A CASE-CONTROL STUDY IN INDIA TO EVALUATE THE EFFECTIVENESS OF SERUM INSTITUTE OF INDIA PVT. LTD.'S LICENSED ROTAVIRUS VACCINE, ROTASIIL.PVS CONTINUED TO CONDUCT EARLY-STAGE CLINICAL TRIALS OF VACCINE CANDIDATES THAT MAY PROVIDE PROTECTION AGAINST ENTEROTOXIGENIC ESCHERICHIA COLI (ETEC) AND SHIGELLA, LEADING CAUSES OF BACTERIAL DIARRHEAL ILLNESS. CURRENTLY, THERE ARE NO LICENSED VACCINES AGAINST EITHER PATHOGEN. IN 2019, OUR WORK INCLUDED CONDUCTING A PHASE 1 TRIAL OF AN ORAL, SUBUNIT ETEC VACCINE CANDIDATE GIVEN WITH AND WITHOUT A NOVEL MUCOSAL ADJUVANT. IN 2019 WE ADVANCED DEVELOPMENT OF A LOW-COST VACCINE TO PROTECT CHILDREN AGAINST PNEUMOCOCCAL BACTERIA, THE TOP CAUSE OF SEVERE CHILDHOOD PNEUMONIA. AFTER POSITIVE CLINICAL TRIAL RESULTS IN THE GAMBIA AND INDIA, THE VACCINE PRODUCED BY SERUM INSTITUTE OF INDIA PVT. LTD., PNEUMOSIL, ACHIEVED WORLD HEALTH ORGANIZATION PREQUALIFICATION, CERTIFYING ITS ELIGIBILITY FOR PROCUREMENT BY UNITED NATIONS AGENCIES FOR USE IN LOW- AND MIDDLE-INCOME COUNTRIES.PVS, AS PART OF THE ADVANCING MATERNAL IMMUNIZATION (AMI) COALITION, ADDED TO THE RESPIRATORY SYNCYTIAL VIRUS (RSV) MATERNAL IMMUNIZATION KNOWLEDGE BASE IN 2019. THE COALITION PUBLISHED SEVERAL ARTICLES ABOUT THE RESULTS OF AND METHODS USED BY AMI TO DEVELOP A ROAD MAP OUTLINING ACTIVITIES NECESSARY TO MOVE RSV DECISION-MAKING AND DELIVERY FORWARD. AMI ALSO CONTRIBUTED A CHAPTER ON THE STATE OF MATERNAL IMMUNIZATION TO A BOOK FOR THE INDIAN ACADEMY OF PEDIATRICS. COALITION MEMBERS ATTENDED THE 2019 WOMEN DELIVER CONFERENCE IN VANCOUVER, BRITISH COLUMBIA, AND HOSTED A DINNER TO ENGAGE GLOBAL MATERNAL HEALTH LEADERS AND DECISION-MAKERS IN CONVERSATIONS AROUND RSV MATERNAL IMMUNIZATION. AMI ALSO UPDATED ITS RSV VACCINE AND MONOCLONAL ANTIBODY SNAPSHOT (WHICH PROVIDES AN OVERVIEW OF THE INTERVENTION PRODUCT LANDSCAPE) AND TRIAL TRACKER (WHICH PROVIDES INFORMATION ON RELATED CLINICAL TRIALS) TO ENSURE ACCESS TO THE MOST UP-TO-DATE RSV INFORMATION.

---

---

Data for this page was sourced from XML published by IRS (public 990 form dataset) from: https://s3.amazonaws.com/irs-form-990/202003179349305550_public.xml